Cost-effectiveness analysis of Abiraterone Acetate versus Docetaxel in the management of metastatic castration-sensitive prostate cancer: Hong Kong’s perspective

Cost-Effectiveness Analysis of Abiraterone Acetate Treatment Compared With Cabacitaxel in Costa Rica, in Patients with Metastatic Castration-Resistant Prostate Cancer That Have Failed to Chemotherapy with Docetaxel

Value in Health ◽

10.1016/j.jval.2014.08.2278 ◽

2014 ◽

Vol 17 (7) ◽

pp. A635

Author(s):

C.A. Obando ◽

Z. Desanvicente-Celis ◽

L. Gonzalez ◽

D. Muschett ◽

F. Gonzalez ◽

...

Keyword(s):

Prostate Cancer ◽

Cost Effectiveness ◽

Costa Rica ◽

Abiraterone Acetate ◽

Castration Resistant ◽

Cost-Effectiveness Analysis of Abiraterone Acetate Treatment Compared with Cabacitaxel in Dominican Republic, in Patients With Metastatic Castration-Resistant Prostate Cancer that Have Failed to Chemotherapy with Docetaxel

Value in Health ◽

10.1016/j.jval.2014.08.2279 ◽

2014 ◽

Vol 17 (7) ◽

pp. A635 ◽

Author(s):

C.A. Obando ◽

Z. Desanvicente-Celis ◽

L. Gonzalez ◽

D. Muschett ◽

F. Gonzalez ◽

...

Keyword(s):

Prostate Cancer ◽

Cost Effectiveness ◽

Dominican Republic ◽

Abiraterone Acetate ◽

Castration Resistant ◽

Abiraterone Acetate Versus Enzalutamide for Metastatic Castration-Resistant Prostate Cancer Post Chemotherapy: Cost Effectiveness Analysis

Value in Health ◽

10.1016/j.jval.2013.08.506 ◽

2013 ◽

Vol 16 (7) ◽

pp. A411 ◽

Author(s):

J. He ◽

T. Li ◽

R. Saadi

Keyword(s):

Prostate Cancer ◽

Cost Effectiveness ◽

Abiraterone Acetate ◽

Castration Resistant ◽

Cost-effectiveness analysis of abiraterone acetate (AA) versus docetaxel (D) for the management of metastatic hormone naïve prostate cancer (mHNPC).

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.6514 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 6514-6514 ◽

Cited By ~ 2

Author(s):

Chethan Ramamurthy ◽

Andres F Correa ◽

Elizabeth A. Handorf ◽

J Robert Beck ◽

Daniel M. Geynisman

Keyword(s):

Prostate Cancer ◽

Cost Effectiveness ◽

Abiraterone Acetate ◽

MP70-12 AN INDIRECT TREATMENT COMPARISON AND COST-EFFECTIVENESS ANALYSIS OF ABIRATERONE ACETATE AND ENZALUTAMIDE FOR THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER POST CHEMOTHERAPY

The Journal of Urology ◽

10.1016/j.juro.2014.02.2211 ◽

2014 ◽

Vol 191 (4S) ◽

Author(s):

Melissa Thompson ◽

Tracy Li ◽

Mary Beth Todd ◽

Margaret K. Yu ◽

Thian Kheoh ◽

...

Keyword(s):

Prostate Cancer ◽

Cost Effectiveness ◽

Abiraterone Acetate ◽

Indirect Treatment Comparison ◽

Treatment Comparison ◽

Castration Resistant ◽

Effectiveness Analysis ◽

Indirect Treatment

Cost-Effectiveness Analysis of Abiraterone Acetate Treatment Compared with Cabacitaxel in the Republic of Panama, in Patients with Metastatic Castration-Resistant Prostate Cancer that Have Failed to Chemotherapy with Docetaxel

Value in Health ◽

10.1016/j.jval.2014.08.2261 ◽

2014 ◽

Vol 17 (7) ◽

pp. A632 ◽

Author(s):

C.A. Obando ◽

Z. Desanvicente-Celis ◽

L. Gonzalez ◽

D. Muschett ◽

F. Gonzalez ◽

...

Keyword(s):

Prostate Cancer ◽

Cost Effectiveness ◽

Abiraterone Acetate ◽

Castration Resistant ◽

Effectiveness Analysis ◽

The Republic

Cost Effectiveness Analysis Of Abiraterone Acetate As Treatment For Metastatic Castration Resistant Prostate Cancer After Failure Of Docetaxel Using Data From Real Life Treatment Praxis In Sweden

Value in Health ◽

10.1016/j.jval.2013.03.655 ◽

2013 ◽

Vol 16 (3) ◽

pp. A134-A135 ◽

Author(s):

U. Persson ◽

S. Nilsson ◽

C. Prûtz ◽

C. Hjortsberg

Keyword(s):

Prostate Cancer ◽

Cost Effectiveness ◽

Real Life ◽

Abiraterone Acetate ◽

Castration Resistant ◽

Effectiveness Analysis ◽

Using Data

Cost-Effectiveness Analysis of Abiraterone Acetate as Second Line Treatment for Metastatic Castration-Resistant Prostate Cancer After Docetaxel Treatment in Japan

Value in Health ◽

10.1016/j.jval.2013.08.532 ◽

2013 ◽

Vol 16 (7) ◽

pp. A415-A416 ◽

Author(s):

H. Shibahara ◽

T. Shiroiwa ◽

K. Nakamura ◽

K. Shimozuma

Keyword(s):

Prostate Cancer ◽

Cost Effectiveness ◽

Abiraterone Acetate ◽

Line Treatment ◽

Second Line ◽

Castration Resistant ◽

Effectiveness Analysis ◽

Docetaxel Treatment

01 / COST-EFFECTIVENESS ANALYSIS OF AN EXERCISE INTERVENTION TARGETING PHYSICAL FUNCTIONING IN LONG TERM SURVIVORS OF PROSTATE CANCER PREVIOUSLY TREATED WITH ANDROGEN DEPRIVATION THERAPY

10.26226/morressier.5afadd8af314ac000849b335 ◽

2018 ◽

Author(s):

Kim Edmunds

Keyword(s):

Prostate Cancer ◽

Cost Effectiveness ◽

Androgen Deprivation Therapy ◽

Physical Functioning ◽

Exercise Intervention ◽

Effectiveness Analysis ◽

Previously Treated ◽

Long Term Survivors

Cost-effectiveness analysis of innovative therapy for patients with newly diagnosed hormone-sensitive metastatic prostate cancer

Clinical Genitourinary Cancer ◽

10.1016/j.clgc.2021.03.022 ◽

2021 ◽

Author(s):

Rémi Pelloux-Prayer ◽

Philomène Schiele ◽

Stéphane Oudard ◽

Gwenaëlle Gravis ◽

François Kleinclauss ◽

...

Keyword(s):

Prostate Cancer ◽

Cost Effectiveness ◽

Metastatic Prostate Cancer ◽

Newly Diagnosed ◽

Innovative Therapy ◽

Effectiveness Analysis ◽

Hormone Sensitive